Device Bar-Coding Advocated By GPOs; FDA Cost Analysis Awaited
This article was originally published in The Gray Sheet
Executive Summary
FDA may decide to pursue a medical device bar-code labeling requirement independently of the rulemaking process for drugs and biologics